Short communication : UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in Southern Brazil

• Autor(a) principal: Cason, Lisiane Turatti
• Data de Publicação: 2012
• Outros Autores: Sprinz, Eduardo, Lazzaretti, Rosmeri Kuhmmer, Kuhmmer, Regina, Agnes, Grasiela, Silveira, Jussara Maria, Basso, Rossana Patricia, Pinheiro, Cezar Arthur Tavares, Silveira, Mariângela Freitas da, Almeida, Silvana de, Ribeiro, Jorge Pinto, Mattevi, Vanessa Sune
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/111605
• topic: Hiperbilirrubinemia; HIV; Terapia antirretroviral de alta atividade; Alelos

Highly active antiretroviral therapy (HAART) has increased the survival of HIV-infected patients. However, adverse effects play a major role in adherence to HAART. Some protease inhibitors (mainly atazanavir and indinavir) act as inhibitors of uridine diphosphate-glucuronosyltransferase (UGT1A1), the enzyme responsible for hepatic conjugation of bilirubin. Variations in the promoter region of the UGT1A1 gene (UGT1A1*28, rs8175347) can influence bilirubin plasma levels, modulating the susceptibility to hyperbilirubinemia. Aiming to analyze the association between UGT1A1*28 allele and hyperbilirubinemia in individuals exposed to HAART, we evaluated 375 HIV-positive individuals on antiretroviral therapy. Individuals carrying the UGT1A1*28 allele had a higher risk of developing severe hyperbilirubinemia [prevalence ratio (PR) = 2.43, 95% confidence interval (CI) 1.08–5.45, p = 0.032] as well as atazanavir users (PR = 7.72, 95% CI = 3.14–18.98, p < 0.001). This is the first description of such an association in Brazilian HIV patients, which shows that in African-American and Euroamerican HAART users, the UGT1A1*28 allele also predisposes to severe hyperbilirubinemia, especially in those exposed to atazanavir.